Efficacy News and Research

RSS
Beneficial design element in sunitinib phase III clinical trial for gastrointestinal stromal tumors

Beneficial design element in sunitinib phase III clinical trial for gastrointestinal stromal tumors

Study provides novel mechanism of action of anti-cancer compound: perifosine

Study provides novel mechanism of action of anti-cancer compound: perifosine

Inhibiting IRE1α-XBP1 pathway impacts survival of myeloma cells

Inhibiting IRE1α-XBP1 pathway impacts survival of myeloma cells

Lilly, Kowa announce results from PREVAIL U.S. study

Lilly, Kowa announce results from PREVAIL U.S. study

Glucocorticoid steroids in intelligent medicine specifically hits relevant cells

Glucocorticoid steroids in intelligent medicine specifically hits relevant cells

Formation of blood vessels in tumors attacked from two angles

Formation of blood vessels in tumors attacked from two angles

Results from A.P. Pharma’s APF530 Phase 3 trial on CINV

Results from A.P. Pharma’s APF530 Phase 3 trial on CINV

KYTHERA receives U.S. patent allowance for ATX-101

KYTHERA receives U.S. patent allowance for ATX-101

Zinc supplementation in young children with serious infections significantly lowers risk of treatment failure

Zinc supplementation in young children with serious infections significantly lowers risk of treatment failure

Personalized medicine and the Human Genome Project

Personalized medicine and the Human Genome Project

Janssen submits canagliflozin NDA with FDA for treatment of type 2 diabetes

Janssen submits canagliflozin NDA with FDA for treatment of type 2 diabetes

Scientists succeed in solving first structure of a Wnt protein

Scientists succeed in solving first structure of a Wnt protein

Top-line results from Genzyme’s teriflunomide Phase III trial on MS

Top-line results from Genzyme’s teriflunomide Phase III trial on MS

Omeros commences planned PK substudy in Phase 3 clinical program of OMS302

Omeros commences planned PK substudy in Phase 3 clinical program of OMS302

FDA approves RBI’s AppliGel-G for human testing

FDA approves RBI’s AppliGel-G for human testing

Vertebroplasty feasible for at least 1 year after fracture

Vertebroplasty feasible for at least 1 year after fracture

Taiho to initiate TAS-102 Phase III trial in colorectal cancer

Taiho to initiate TAS-102 Phase III trial in colorectal cancer

Top-line data from Flexion‘s FX005 Phase 2 trial on osteoarthritis

Top-line data from Flexion‘s FX005 Phase 2 trial on osteoarthritis

Interim data from UCLA and NeuroSigma’s eTNS Phase I trial on PTSD, MDD

Interim data from UCLA and NeuroSigma’s eTNS Phase I trial on PTSD, MDD

BHD launches Statin Induced Myopathy Genotype test

BHD launches Statin Induced Myopathy Genotype test

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.